App-Quantinova.ai

A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Peter Hillmen - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

ACP-196

TRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making

Edward Bataillard - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non-Hodgkin's Lymphoma

Cyclophosphamide

Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia

Simone Claudiani - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

N/A

Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients

Tiziano Barbui - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Myeloid neoplasms

Hydroxyurea

The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells

Jennifer A Mertz - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Myelofibrosis

Ruxolitinib phosphate

Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN

Charlotte K Brierley - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

Ruxolitinib phosphate

MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI‑0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients

John Mascarenhas - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Essential thrombocythemia

Ruxolitinib phosphate

An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib

John Mascarenhas - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Ruxolitinib phosphate

Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval

Srdan Verstovsek - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Alpha-thalassemia myelodysplasia syndrome

Ruxolitinib phosphate

JMML Fetal Identity Results Either from Retention of a Physiologic Signature or Aberrant Activation of Master Oncofetal Regulators

Marion Strullu - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Leukemia, juvenile myelomonocytic

N/A

Sequential Analysis of miRNA Profiling during Azacitidine and Lenalidomide Therapy in Myelodysplastic Syndromes

Matilde Y Follo - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelodysplastic Syndrome

Lenalidomide

Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the MEDALIST Study

Rami S. Komrokji - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

Erythropoietin

Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia

Zhenghao Chen - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Ibrutinib

The Association between Deaths Due to Infection and Mutations of the BRAF, FBXW7, NRAS and XPO1 genes: A Report from the LRF CLL4 Trial

Monica Else - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Cyclophosphamide

Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study

Rosemary Anne Harrup - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Venetoclax

Acalabrutinib Vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Ascend Final Results

Paolo Ghia - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

ACP-196

Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Chronic Lymphocytic Leukemia

ACP-196

Mutations in CRBN and Other Cereblon Pathway Genes Are Only Associated with Acquired Resistance to Immunomodulatory Drugs in a Subset of Patients and Cell Line Models

Amy Barber - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Pomalidomide

Panobinostat in Combination with Bortezomib and Dexamethasone for Heavily Pre-Treated Myeloma: A UK Real-World Multi-Centre Cohort

Nadjoua Maouche - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Real-World Evidence of the Use of Approved Carfilzomib Regimens in Patients Previously Exposed or Refractory to Lenalidomide: Updated Results from a Prospective Observational Study

Xavier Leleu - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Lenalidomide

Filters

45280 Abstracts